摘要
2018年,欧洲肿瘤内科学会(European Society for Medical Oncology,ESMO)和日本、中国、韩国等亚洲各国胃癌治疗领域的专家以科学证据为基础,在胃癌诊疗方面达成共识,修订了2016年发布的《ESMO胃癌诊断、治疗和随访的临床实践指南》,以更适应对亚洲胃癌的管理和治疗。2019年ESMO转移性胃癌指南最大的更新是免疫治疗部分:①在生物标志物方面,可考虑进行微卫星不稳定和错配修复基因、程序性死亡蛋白配体1、肿瘤突变负荷以及EB病毒的检测;②在药物治疗方面,更新了免疫检查点抑制剂纳武利尤单抗、帕博丽珠单抗在晚期胃癌治疗中的应用。该指南的更新体现了胃癌进入免疫治疗时代。
In 2018, the European Society for Medical Oncology(ESMO) and the oncologists from Asian countries including Japan,China, Korea reached consensus, based on scientific evidences, on the diagnosis, treatment and follow-up of gastric cancer(GC) and revised the 2016 version. The main change in 2019 ESMO metastatic gastric cancer guidelines is the updates of immunotherapy.Microsatellite instability(MSI)/mismatch repair defect(dMMR), programmed death ligand 1(PD-L1), tumor mutation burden(TMB)and Epstein Barr virus(EBV) status may be considered as biomarkers. The guideline also summarizes the application of checkpoint inhibitors Nivolumab and Pembrolizumab in advanced gastric cancer. These updates suggest that the age of immunotherapy of gastric cancer has come.
作者
刘芹
刘宝瑞
LIU Qin;LIU Bao-rui(the Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University & ClinicalCancer Institute of Nanjing University, Nanjing 210008, China)
出处
《肿瘤综合治疗电子杂志》
2019年第2期97-101,共5页
Journal of Multidisciplinary Cancer Management(Electronic Version)
基金
国家重点研发计划专项经费资助(2017YFC1308900)
江苏省医学青年人才(QNRC2016045)
关键词
转移性胃癌
亚洲
共识
ESMO指南
Metastatic gastric cancer
Asia
Consensus
ESMO guidelines
